ATE439137T1 - Behandlung von hämatologischen störungen - Google Patents

Behandlung von hämatologischen störungen

Info

Publication number
ATE439137T1
ATE439137T1 AT98960199T AT98960199T ATE439137T1 AT E439137 T1 ATE439137 T1 AT E439137T1 AT 98960199 T AT98960199 T AT 98960199T AT 98960199 T AT98960199 T AT 98960199T AT E439137 T1 ATE439137 T1 AT E439137T1
Authority
AT
Austria
Prior art keywords
treatment
hematological disorders
neoplastic
gvhd
hematologic
Prior art date
Application number
AT98960199T
Other languages
English (en)
Inventor
Megan Sykes
Thomas Spitzer
Original Assignee
Gen Hospital Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gen Hospital Corp filed Critical Gen Hospital Corp
Application granted granted Critical
Publication of ATE439137T1 publication Critical patent/ATE439137T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/22—Immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/418—Antigens related to induction of tolerance to non-self
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/809—Drug, bio-affecting and body treating compositions involving immunoglobulin or antibody fragment, e.g. fab', fv, fc, heavy chain or light chain
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/81—Packaged device or kit

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Mechanical Treatment Of Semiconductor (AREA)
  • Cereal-Derived Products (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT98960199T 1997-11-14 1998-11-13 Behandlung von hämatologischen störungen ATE439137T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7323097P 1997-11-14 1997-11-14
PCT/US1998/024209 WO1999025367A2 (en) 1997-11-14 1998-11-13 Treatment of hematologic disorders

Publications (1)

Publication Number Publication Date
ATE439137T1 true ATE439137T1 (de) 2009-08-15

Family

ID=22112521

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98960199T ATE439137T1 (de) 1997-11-14 1998-11-13 Behandlung von hämatologischen störungen

Country Status (8)

Country Link
US (3) US6558662B2 (de)
EP (1) EP1030675B1 (de)
JP (1) JP2001523645A (de)
AT (1) ATE439137T1 (de)
AU (1) AU1585799A (de)
CA (1) CA2309919A1 (de)
DE (1) DE69841058D1 (de)
WO (1) WO1999025367A2 (de)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69841058D1 (de) * 1997-11-14 2009-09-24 Gen Hospital Corp Behandlung von hämatologischen störungen
WO2000045842A2 (en) * 1999-02-04 2000-08-10 The General Hospital Corporation Methods for human allografting
DE10050334A1 (de) * 2000-10-11 2002-04-25 Gsf Forschungszentrum Umwelt Verwendung von Stammzellen und CD6-depletierten Stammzellen zur Toleranzinduktion gegenüber allogenen Transplantaten und/oder zur Leukämiebehandlung
WO2002040049A2 (en) * 2000-11-14 2002-05-23 The General Hospital Corporation Blockade of t cell migration into epithelial gvhd target tissues
US20030031652A1 (en) * 2001-04-16 2003-02-13 Bernhard Hering Systems and methods for inducing mixed chimerism
WO2002089746A2 (en) * 2001-05-09 2002-11-14 The University Of Louisville Research Foundation, Inc. Hematopoietic stem cell chimerism to treat autoimmune disease
US20030147859A1 (en) * 2001-06-18 2003-08-07 Yair Reisner Methods of utilizing cultured hematopoietic progenitor cells for inducing immunological tolerance
US20030032631A1 (en) * 2001-08-13 2003-02-13 Mcdonald George B. Method of treatment of cancer by controlling graft-versus-leukemia using topical active corticosteriods
EP1549277A4 (de) * 2002-05-22 2007-09-05 Cleveland Clinic Foundation Einleitung und aufrechterhaltung von toleranz gegenüber zusammengesetzten gewebe-allotransplantaten
US20050058641A1 (en) * 2002-05-22 2005-03-17 Siemionow Maria Z. Tolerance induction and maintenance in hematopoietic stem cell allografts
US20040071666A1 (en) * 2002-05-24 2004-04-15 The Regents Of The University Of Michigan Compositions and methods related to graft-versus-host disease
US20050058622A1 (en) * 2002-12-06 2005-03-17 Lyman Stewart D. Methods of using Flt3-Ligand in hematopoietic cell transplantation procedures incorporating nonmyeloablative conditioning regimens
NZ566132A (en) * 2003-02-13 2009-09-25 Anthrogenesis Corp Use of umbilical cord blood to treat inflammation, ParkinsonÆs disease or diabetes
JP2004256444A (ja) * 2003-02-26 2004-09-16 Kansai Tlo Kk 悪性腫瘍の治療方法
US7435592B2 (en) 2003-05-13 2008-10-14 Immunovative Therapies, Ltd. Compositions for allogeneic cell therapy
WO2005021734A2 (en) * 2003-09-02 2005-03-10 University Of Massachussets Generation of hematopoietic chimerism and induction of central tolerance
WO2005030999A1 (en) * 2003-09-25 2005-04-07 Dana-Farber Cancer Institute, Inc Methods to detect lineage-specific cells
EP1689435A4 (de) * 2003-10-22 2007-10-03 Univ Rochester Anti-thymozyten-antiserum und seine verwendung zur auslösung von b-zell-apoptose
US8252587B2 (en) 2004-10-25 2012-08-28 Celerant Therapeutics, Inc. Methods of expanding myeloid cell populations and uses thereof
JP2007087270A (ja) * 2005-09-26 2007-04-05 Tsukuba Brains Kk 再生医療支援システム
WO2007065167A1 (en) * 2005-12-02 2007-06-07 The Johns Hopkins University Use of high-dose oxazaphosphorine drugs for treating immune disorders
US20070179810A1 (en) * 2006-01-05 2007-08-02 Goodman Edward L Controls for antimicrobial use and infection
WO2007095594A2 (en) * 2006-02-14 2007-08-23 Cellerant Therapeutics, Inc. Methods and compositions for enhancing engraftment of hematopoietic stem cells
WO2008034074A2 (en) 2006-09-15 2008-03-20 The Johns Hopkins University Cyclosphosphamide in combination with anti-idiotypic vaccines
WO2008034076A2 (en) 2006-09-15 2008-03-20 The Johns Hopkins University Cyclophosphamide in combination with immune therapeutics
WO2008034071A2 (en) 2006-09-15 2008-03-20 The Johns Hopkins University Method of identifying patients suitable for high-dose cyclophosphamide treatment
WO2008128299A1 (en) * 2007-04-24 2008-10-30 Murdoch Childrens Research Institute Therapeutic protocol for treating hemoglobinopathy
WO2009067699A2 (en) * 2007-11-21 2009-05-28 Accentia Biopharmaceuticals, Inc. Methods for providing a system of care for an oxazaphosphorine drug regimen
US9026372B2 (en) * 2007-11-21 2015-05-05 Accentia Biopharmaceuticals, Inc. Methods for providing a system of care for a high-dose oxazaphosphorine drug regimen
KR101604649B1 (ko) * 2007-11-27 2016-03-18 베리덱스, 엘엘씨 혈액 내 순환 흑색종 세포의 자동화된 계산 및 특징화
CA2732228A1 (en) * 2008-07-25 2010-01-28 The Johns Hopkins University Methods and compositions for treating and preventing autoimmune diseases
US9682106B2 (en) 2011-04-20 2017-06-20 The Regents Of The University Of California Method for combined conditioning and chemoselection in a single cycle
RU2611396C2 (ru) 2011-04-20 2017-02-21 Де Реджентс Оф Де Юниверсити Оф Калифорния Способ совместного кондиционирования и хемоселекции за один цикл
RU2657758C2 (ru) 2011-12-22 2018-06-15 Иеда Рисеч Энд Девелопмент Ко. Лтд. Комбинированная терапия для стабильного и долговременного приживления трансплантата
EP3498305A1 (de) * 2012-04-20 2019-06-19 Angimmune Llc Immunmodulation durch anti-cd3-immuntoxine zur behandlung von karzinomen ohne einheitliches oberflächen-cd3
CN113476478A (zh) 2013-02-26 2021-10-08 小利兰·斯坦福大学托管委员会 实现移植物移植耐受的联合器官和造血细胞
US11116777B2 (en) 2015-11-10 2021-09-14 City Of Hope Conditioning regimens and methods for inducing mixed chimerism
US12485186B2 (en) 2017-03-31 2025-12-02 The Children's Medical Center Corporation Antibody-mediated conditioning with immunosuppression to enable allogeneic transplantation
EP3654994B1 (de) 2017-07-18 2022-12-28 CSL Behring Gene Therapy, Inc. Modulierbarer schalter zur auswahl von donormodifizierten zellen
BR112020010816A2 (pt) * 2017-11-29 2020-11-10 Magenta Therapeutics, Inc. composições e métodos para a depleção de células de cd2+
AU2018374283B2 (en) 2017-11-29 2025-09-18 Magenta Therapeutics, Inc. Compositions and methods for the depletion of CD5+ cells
EP3765044A4 (de) 2018-03-12 2021-12-08 Medeor Therapeutics, Inc. Verfahren zur behandlung von nichtkanzerösen erkrankungen unter verwendung von hämatopoetischen zellen
US10881692B2 (en) 2018-04-05 2021-01-05 Medeor Therapeutics, Inc. Compositions for establishing mixed chimerism and methods of manufacture thereof
US10842821B2 (en) 2018-04-05 2020-11-24 Medeor Therapeutics, Inc. Cellular compositions derived from prior organ donors and methods of manufacture and use thereof
US11813376B2 (en) 2018-09-18 2023-11-14 Medeor Therapeutics, Inc. Cellular compositions derived from deceased donors to promote graft tolerance and manufacture and uses thereof
US11435350B2 (en) 2018-09-18 2022-09-06 Medeor Therapeutics, Inc. Methods of analysis of blood from deceased donors
AU2019374055B2 (en) * 2018-10-30 2026-06-11 Regeneron Pharmaceuticals, Inc. Methods for allogeneic hematopoietic stem cell transplantation
JP2022505615A (ja) * 2018-10-31 2022-01-14 マジェンタ セラピューティクス インコーポレイテッド 造血幹・前駆細胞移植療法の方法
US11697799B2 (en) 2019-04-15 2023-07-11 Ossium Health, Inc. System and method for extraction and cryopreservation of bone marrow
WO2020216947A1 (en) 2019-04-24 2020-10-29 Heidelberg Pharma Research Gmbh Amatoxin antibody-drug conjugates and uses thereof
EP3965782A4 (de) * 2019-05-09 2023-03-08 The General Hospital Corporation Verfahren zur induktion von hämatopoetischem chimärismus
BR112022008700A2 (pt) * 2019-11-05 2022-07-19 Yeda Res & Dev Método para tratar ou prevenir uma doença falciforme, e, transplante de células hematopoiéticas imaturas e uma quantidade terapeuticamente eficaz de uma população isolada de células anti-terceiros não indutoras de doença do enxerto versus hospedeiro
EP4142755A4 (de) * 2020-04-27 2024-06-12 Children's Hospital Medical Center Präzisionsdosierschema
CN116234557A (zh) * 2020-08-18 2023-06-06 希望之城 用于治疗自身免疫性疾病的单倍体相合混合嵌合状态
EP4229183A4 (de) 2020-10-14 2024-12-11 Ossium Health, Inc. Zusammensetzungen und verfahren zur extraktion mesenchymaler stammzellen
CN116829185A (zh) * 2020-11-18 2023-09-29 加利福尼亚大学董事会 耗竭抗自然杀伤细胞的单克隆抗体
EP4262831A4 (de) * 2020-12-18 2025-01-01 Ossium Health, Inc. Verfahren für zelltherapien

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4281061A (en) * 1979-07-27 1981-07-28 Syva Company Double antibody for enhanced sensitivity in immunoassay
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US5004681B1 (en) 1987-11-12 2000-04-11 Biocyte Corp Preservation of fetal and neonatal hematopoietic stem and progenitor cells of the blood
US5192553A (en) 1987-11-12 1993-03-09 Biocyte Corporation Isolation and preservation of fetal and neonatal hematopoietic stem and progenitor cells of the blood and methods of therapeutic use
AU679437B2 (en) * 1992-01-08 1997-07-03 General Hospital Corporation, The Induced tolerance to xenografts
US5834266A (en) 1993-02-12 1998-11-10 President & Fellows Of Harvard College Regulated apoptosis
US5730979A (en) 1993-03-05 1998-03-24 Universite Catholique Delouvain LO-CD2a antibody and uses thereof for inhibiting T cell activation and proliferation
ATE205531T1 (de) 1993-03-05 2001-09-15 Univ Catholique Louvain Lo-cd2a antikörper und dessen verwendung zur inhibition von t-zell-aktivierung und -wachstum
WO1995003062A1 (en) * 1993-07-21 1995-02-02 Cellpro, Incorporated Methods and compositions for preventing immune rejection of solid organ grafts
US5635156A (en) 1993-09-13 1997-06-03 University Of Pittsburgh Non-lethal methods for conditioning a recipient for bone marrow transplantation
US5484612A (en) * 1993-09-22 1996-01-16 The Board Of Trustees Of The Leland Stanford Junior University Method of treating a mammal having a solid tumor susceptible to treatment with cisplatin
US5599703A (en) 1993-10-28 1997-02-04 The United States Of America As Represented By The Secretary Of The Navy In vitro amplification/expansion of CD34+ stem and progenitor cells
WO1995026740A1 (en) * 1994-03-31 1995-10-12 Diacrin, Inc. Improved methods for transplantation using modified cells and t cell inhibitory agents
CA2196311A1 (en) 1994-08-19 1996-02-29 David H. Sachs Genetically engineered swine cells
US6006752A (en) * 1996-05-09 1999-12-28 The General Hospital Corporation Mixed chimerism and tolerance
IL129573A0 (en) 1996-11-15 2000-02-29 Baxter Int Conditioning for allogeneic stem cell transplantation
DE69841058D1 (de) * 1997-11-14 2009-09-24 Gen Hospital Corp Behandlung von hämatologischen störungen

Also Published As

Publication number Publication date
CA2309919A1 (en) 1999-05-27
US20090028870A1 (en) 2009-01-29
WO1999025367A3 (en) 1999-08-05
US20030157077A1 (en) 2003-08-21
EP1030675A2 (de) 2000-08-30
AU1585799A (en) 1999-06-07
WO1999025367A2 (en) 1999-05-27
JP2001523645A (ja) 2001-11-27
US20010048921A1 (en) 2001-12-06
US6558662B2 (en) 2003-05-06
EP1030675B1 (de) 2009-08-12
US7408039B2 (en) 2008-08-05
DE69841058D1 (de) 2009-09-24
US7892578B2 (en) 2011-02-22

Similar Documents

Publication Publication Date Title
DE69841058D1 (de) Behandlung von hämatologischen störungen
BG110703A (en) PHARMACEUTICAL COMPOSITION, INCLUDING HUMAN ANTIBODIES CONNECTING HUMAN TNF ALPHA AND HIS APPLICATION
PL328858A1 (en) Immunogenous peptides
MY129189A (en) Prostaglandin agonists and their use to treat bone disorders
ATE326239T1 (de) Verfahren zur behandlung von ig-e assozierten krankheiten und zusammensetzungen zur verwendung in diesen verfahren
DE3483040D1 (de) Maschinelesbares dokument und dessen behandlung.
NO166943C (no) Analogifremgangsmaate for fremstilling av enzymresistente immunomodulerende peptider.
DE69830072D1 (de) Radioaktive zusammensetzungen zur behandlung von prostatatumoren
WO2001023405A3 (en) Therapeutic treatment of androgen receptor driven conditions
MXPA02000119A (es) Elementos mezcladores estaticos apilados.
DE69830336D1 (de) Ein kovalentes konjugat von clozapine und einer fettsäure und dessen verwendung zur behandlung von schizophrenie
ATE296634T1 (de) (s,s)-reboxetin zur behandlung von fibromyalgie und anderen somatoformen störungen
DK1039912T3 (da) Angiostatiske midler og præparater til behandling af GLC1A-glaukom
ATE362374T1 (de) Verfahren und zusammensetzungen zur prevention oder behandlung von krebs und von krebs assoziertem knochenverlust
IL134445A0 (en) A method of preventing or treating estrogen-dependent diseases and disorders
ATE311853T1 (de) Verwendung von krillenzymen zur behandlung von zahnbelag
TW200640944A (en) VGF polypeptides and methods of treating VGF-related disorders
GB9009106D0 (en) Processes and intermediates for synthetic antibody derivatives
DE69113221D1 (en) Antiatherosclerotische und antithrombotische 2-amino-6-phenyl-4h-pyran-4-one.
IL141550A0 (en) Methods and compositions for the prevention or treatment of cancer
MXPA02000680A (es) Polipeptidos vgf y metodos para tratar desordenes relacionados con vgf.
ATE220557T1 (de) Darmprotozoen-impfstoffe
ATE261724T1 (de) Antikonvulsive derivate zur behandlung von posttraumatischen stresserkrankungen
DE69835828D1 (de) Muc-1 derivate und deren verwendung zur behandlung von krebsassoziierter muc-1 mucin induzierter immunosuppression
DK1161250T3 (da) Immunstimulerende bakteriemembranfraktioner i cancerbehandling

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties